DNA

Exousia Pro Creates New Subdivisions

Exousia Pro aims to develop three new subdivisions and launch new products during the 4th quarter.The market for our new…

4 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming…

4 months ago

Quotient Sciences and CPI to Accelerate RNA Drug Development with Joint Venture

NOTTINGHAM, England, Sept. 2, 2025 /PRNewswire/ -- Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation…

4 months ago

MicroGenDX’s New Testing Platform Cuts NGS Turnaround Time to 24 Hours for Life-Saving Decisions

Adoption of Illumina's MiSeq i100 Plus accelerates results delivery to next-day from sample receipt, speeding up patient care when time…

4 months ago

Predicine Submits First Module of PMA Application to FDA for PredicineCARE™ as a Companion Diagnostic Assay in Bladder Cancer

HAYWARD, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, today announced the submission of…

4 months ago

Digital Pathology Market to Grow at a CAGR of 7.8% from 2025 to 2032 | SkyQuest Technology Consulting

The digital pathology market is anticipated to increase due to the global increase in chronic conditions like cancer, cardiovascular disorders,…

4 months ago

Anavar For Women And Men: CrazyBulk Launch Anavar Legal Steroid Alternative For Female Read Dosage, Side Effects, (Before and After Cycle results)

Anavar is a potent anabolic steroid Alternative Pills for men and women that is popular among bodybuilders and athletes in…

4 months ago

Memory Lift Reviews: Does This Supplement Improve Brain Health? Everything You Need To Know Before Buying

MIAMI, FL / ACCESS Newswire / August 30, 2025 / In today's fast-paced world, maintaining mental sharpness, focus, and memory…

4 months ago

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting…

4 months ago

Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions

BOSTON, Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURTNORTHERN DISTRICT OF…

4 months ago